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Abstract 
Withdrawal from long-term dosing with exogenous progesterone precipitates increased anxiety-
linked changes in behavior in animal models due to the abrupt decrease in brain concentration of 
allopregnanolone (ALLO), a neuroactive metabolite of progesterone. We show that a withdrawal-
like effect also occurs during the late diestrus phase (LD) of the natural ovarian cycle in rats, when 
plasma progesterone and ALLO are declining but estrogen secretion maintains a stable low level. 
This effect at LD was prevented by short-term treatment with low dose fluoxetine.  
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During LD, but not at other stages of the estrous cycle, exposure to anxiogenic stress induced by 
whole body vibration at 4Hz for 5min evoked a significant decrease in tail flick latency (stress-
induced hyperalgesia) and a decrease in the number of Fos-positive neurons present in the 
periaqueductal gray (PAG). The threshold to evoke fear-like behaviors in response to electrical 
stimulation of the dorsal PAG was lower in the LD phase, indicating an increase in the intrinsic 
excitability of the PAG circuitry. All these effects were blocked by short-term administration of 
fluoxetine (2 x 1.75mg kg-1 i.p.) during LD. This dosage increased the whole brain concentration 
of ALLO, as determined using gas chromatography - mass spectrometry, but was without effect 
on the extracellular concentration of 5-HT in the dorsal PAG, as measured by microdialysis.  
We suggest that fluoxetine-induced rise in brain ALLO concentration during LD offsets the sharp 
physiological decline, thus removing the trigger for the development of anxiogenic withdrawal 
effects.  
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1. Introduction   
Premenstrual syndrome (PMS) and its more severe counterpart: premenstrual dysphoric disorder, blights 
the lives of millions of women worldwide (Steiner, 1997). In susceptible women the symptoms, which 
include angry outbursts, irritability and anxiety (ACOG, 2001), can be considered an exaggerated and  
inappropriate response to everyday acute stressful challenges. Surprisingly, given the enormity of the 
problem of PMS, there has been relatively little basic scientific study into its neurophysiological basis. 
 3
What is clear from clinical studies is that PMS is dependent on cyclical variations in female sex hormones. 
Symptoms do not appear in anovulatory cycles (Backström et al., 2003). However ovulation itself is not 
the key factor since many women taking the combined contraceptive pill on a 21 day on, 7 day off dosing 
regimen, which prevents ovulation, also experience PMS-like symptoms, which peak during the 7 day 
drug free period (Kadian and O’Brien, 2012). In both cycling women and those taking the pill, symptoms 
occur at a time when blood levels of progesterone and estrogen, or their synthetic analogues, are in rapid 
decline. 
In rats, withdrawal from long term dosing with exogenous progesterone at doses sufficient to raise 
progesterone to the high physiological range, precipitates increased anxiety ( Smith et al., 1998; Smith et 
al., 2006). Spontaneously cycling rats in the late diestrus phase, when progesterone secretion declines 
sharply but estrogen secretion remains at a stable low level (Butcher et al., 1974), also become more 
fearful in an open field arena (Devall et al., 2009).  Moreover, exposure of rats to 5min of mild anxiogenic 
vibration stress (5min vibration at 4Hz whilst confined in a tube, Jørum 1988) during late diestrus evokes 
a hyperalgesia, which is not seen when the animals are exposed to the same stressor at other stages of the 
cycle (Devall et al., 2009).  These findings suggest that falling progesterone predisposes to an enhanced 
response to psychogenic stress. By analogy, the rapid decline in ovarian progesterone secretion in women 
during the late luteal phase might also provide a trigger for the enhanced responsiveness to psychogenic 
stress, which is a feature of the premenstrual period in many women (Nilni et al., 2011; Hoyer et al., 2013; 
Gollenberg et al., 2010). Thus whilst the cause of PMS in women is likely to be multifactorial, withdrawal 
from progesterone could be a significant contributory precipitating factor. 
Progesterone passes readily through the blood brain barrier. The active agent that triggers the neuronal 
response to progesterone withdrawal in female rats is not however the native steroid hormone, but its 
neuroactive metabolite allopregnanolone (ALLO: 5-pregnan-3-ol-20-one or 3,5-
tetrahydroprogesterone) (Gulinello et al., 2003; Smith et al., 1998). This progesterone metabolite ALLO is 
a potent positive allosteric modulator of the actions of GABA at GABAA receptors (Paul and Purdy, 1992) 
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and its concentration in random cyclic female rat brain correlates with that of its precursor progesterone in 
plasma (Corpéchot et al., 1993). Ovarian secretion of both progesterone and ALLO decreases sharply at 
late diestrus (Ichikawa et al., 1974; Holzbauer, 1975), and so the concentration of ALLO in the brain will 
decrease in parallel. There is some endogenous production of progesterone and ALLO in the male rat 
brain (Cook et al., 2014). A similar situation appears to exist in the female rat, as evidenced by the 
persistence of these steroids in the brains of ovariectomised and adrenalectomised animals, but this is at 
concentrations around 9-fold and 40-fold lower, respectively, than those seen in the brains of intact 
random cycling rats (Corpéchot et al., 1993). Even in female rats at late diestrus, when ovarian 
progesterone secretion is low, brain concentrations of ALLO and progesterone were 10-fold higher than in 
males (Fry et al., 2014). Whether naturally during the ovarian cycle or following administration of 
exogenous progesterone, withdrawal from ALLO, triggers upregulation of extrasynaptic GABAA 
receptors in the brain and consequent changes in excitability of neuronal circuits associated with anxiety 
(Gangisetty and Reddy, 2010; Griffiths and Lovick, 2005a; Griffiths and Lovick, 2005b; Gulinello et al., 
2003; Lovick et al., 2005; Smith et al., 1998). The dynamic of the fall in brain concentration of 
progesterone appears critical because abrupt withdrawal from an exogenous progesterone-dosing regimen 
in rats precipitates an increase in responsiveness to anxiogenic stressors, whilst a gradually tapered 
withdrawal does not (Doornbos et al., 2009 ; Saavedra et al., 2006).  In this respect it is interesting that in 
women, an association between clinical features of PMS and rate of decrease in progesterone during the 
luteal phase has been noted (Halbreich et al., 1986). Thus we reasoned that if the sharp fall in brain ALLO 
concentration that occurs at the end of the estrous cycle in rats is a trigger for the development of 
increased stress sensitivity, measures to produce a more gradual reduction in brain concentration of ALLO 
at the end of the estrous cycle should prevent the development of withdrawal-like symptoms.  
In male rats and mice, the antidepressant fluoxetine (FLX) has been shown to induce an increase 
in the concentration of ALLO in the brain, which can be detected within 20 min of acute 
administration (Pinna et al., 2009; Serra et al., 2001; Uzunov et al., 1996). We therefore 
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hypothesized that if FLX produces a similar effect in female rats in late diestrus, then short term 
dosing with FLX during this stage of the ovarian cycle should offset the rapid physiological fall in 
the concentration of ALLO. Further, that the stimulus for the development of withdrawal effects, 
which normally characterise this phase of the ovarian cycle, should be absent and changes in 
behavioral responsiveness to stress should not occur. To test this hypothesis we chose to focus on 
changes in neuronal responsiveness in the PAG, since we have already shown that estrous cycle-
linked changes in GABAA receptor expression and neuronal excitability occur in this structure 
alongside changes in behavioral responsiveness (Lovick et al., 2005; Devall et al., 2009; 2011). 
Moreover electrical stimulation of the PAG evokes behavior that characterises responses to 
threatening and hence stressful situations in the rat and is sensitive to actions of anxiolytic drugs 
(Borelli et al., 2004).  
 
2. Experimental procedures 
The following is a brief outline of the Methods used. Detailed descriptions are available as a 
Supplementary File.  
2. 1 Animals and drug treatment regimen 
The estrous cycle of female Wistar rats was established from daily vaginal smears taken at 
approximately 09.00h and only rats that had displayed at least two regular cycles used for the 
present study. Based on vaginal cytology, cycle stages were classified as follows:  proestrus:  
mainly lymphocytes; estrus: mainly cornified cells; early diestrus: mainly leucocytes with well-
defined lobular nuclei; late diestrus: fewer cells than in early diestrus, nucleus “clumped”, 
presence of amorphous, disintegrating leucocytes (Brack and Lovick, 2007). Fluoxetine 
hydrochloride (FLX) (Sigma, 1.75 mg kg-1 i.p.) or saline vehicle was administered at 16:30-17:00 
h on the evening of early diestrus. A second dose of fluoxetine or the saline vehicle was given in 
late diestrus the following morning 1h prior to behavioral or neurochemical testing.  The animals 
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allocated for brain steroid measurement were killed by decapitation and the whole brain, minus the 
olfactory bulbs, removed rapidly and stored frozen at -80oC until analysis. The dose of FLX was 
chosen as one that has been shown in male rats to produce a significant rise in brain concentration 
of ALLO (Uzunov et al., 1996) but is below the dose reported to produce significant rises in brain 
5-HIAA and 5-HT levels (Fuller et al., 1974; Rutter and Auerbach, 1993) or to produce 
behaviorally measurable effects via actions on brain 5-HT systems after acute administration in 
vivo (10mg kg-1) (Silva and Brandão, 2000).  
 
2.2 Neurochemical studies 
2.2.1 Brain allopregnanolone measurement 
To establish whether the effects of FLX in preventing the behavioral and neuronal changes that 
normally occurred during late diestrus could be due to a steroidogenic action of the drug, we 
measured allopregnanolone concentration in whole brain homogenates. Rats were dosed with FLX 
(1.75mg kg-1 i.p.) or vehicle on the afternoon of early diestrus and again on the next morning 
when they were in late diestrus (see 2.1). In order to eliminate the possibility of eliciting stress-
induced increases in allopregnanolone, this group of rats did not undergo behavioral testing. They 
were killed by decapitation 1h after receiving the final dose on the morning of late diestrus. The 
brain was removed rapidly, separated from the olfactory bulbs and the tissue immediately snap 
frozen in solid CO2 pellets. Tissue was then stored at -80oC prior to analysis of steroid content.  
Following extraction and fractionation of free steroids, the concentration of 
allopregnanolone in brain homogenates was measured by selective ion monitoring of its 
methyloxime trimethylsilyl ether through gas chromatography - mass spectrometry (GC-MS), 
using the procedures described by Ebner and co-workers (Ebner et al., 2006) (for more details see 
Supplementary file). 
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2.2.2 Measurement of extracellular 5-HT concentration. 
Guide cannulae were chronically implanted into the dPAG in 14 rats (see Supplementary file for 
details). Following a recovery period of 5 to 7 days, rats in the afternoon of their early diestrus 
phase were treated with FLX (1.75 or 10mg kg-1 i.p.) or saline following the same dosing protocol 
used for behavioral experiments (see above). Next day, in the morning of late diestrus, a 
microdialysis probe was inserted into the dPAG via the guide cannula. A stabilization period of 2h 
was allowed before commencing sample collection. First, samples of dialysate were collected 
every 30 min over a further 2h period to establish baseline values. The second injection of 
fluoxetine was then given and 6 more samples of dialysate were collected every 30 minutes. Thus 
the effect of FLX on concentration of 5-HT in the extracellular fluid in the dPAG was tested over 
the equivalent time period that behavioral testing was carried out in other groups of rats (see 
above). Since the dose of FLX that produced effects on behavior had no effect on extracellular 5-
HT concentration in the PAG (see Results 3.1.2.2), as a positive control we also administered FLX 
at a higher dose of (10mg kg-1) to another group of rats in late diestrus, in order to ensure that our 
system was able to detect changes in 5-HT concentration. 
 
2.3 Behavioral studies 
2.3.1 Induction of stress-induced hyperalgesia 
Each rat was habituated, over three daily 30min sessions, to being constrained in a plexiglass tube 
in which it could rest comfortably but not turn around. Nociceptive threshold was assessed using 
the tail flick reflex in response to radiant heat applied to a 3mm diameter spot on the blackened 
underside of the tail. Tail flick latencies were measured at 5min intervals to establish a baseline 
(mean of 3 tail flick tests) before subjecting the rat to 5min of anxiogenic stress by vibrating the 
restraining tube at 4Hz for 5min. Tail flick testing then resumed for a further 20min (Devall et al., 
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2009).  Experiments were carried out on rats at all stages of the estrous cycle but each rat was 
tested only once, in order to avoid the possibility of learned effects due to repeated testing. 
Wherever possible, the experimenter was blinded to the estrous cycle stage of the animal. In all 
experiments, a video recording was made, so that behavior could be analysed off-line by other 
observers who were blinded to hormonal status. 
 
2.3.2 Behavioral responses to direct electrical activation of the periaqueductal grey matter 
Bipolar stimulating electrodes were chronically implanted into sites in the dorsal half of the 
periaqueductal gray matter (dPAG) (see Supplementary file for details). The PAG was stimulated 
for 10s periods (60Hz sine wave, intensity increased in 5A increments) at pseudorandom 
intervals (30-120s) in order to determine the threshold current intensity needed to evoke the 
following behaviors (Brandão et al., 2008): 
1. freezing (cessation of all movement apart from breathing, believed to represent evaluation of a 
distal threat),  
2. escape (running and/or jumping, a measure of the response to proximal threat),   
3. post-escape freezing (freezing that occurred after interruption of PAG stimulation at escape 
threshold).  
The effect of PAG stimulation was tested on each rat at the four stages of its estrous cycle. The 
stage at which it was first tested was assigned randomly.  
 
2.4 Functional activation of neurons in the PAG. 
The effect of vibration stress on expression of the immediate early gene c-fos was examined in 
animals that had undergone behavioral testing for stress-induced hyperalgesia. Following the 
stress-testing protocol (see above) rats were returned to their home cages. Two hours following 
the exposure to vibration stress or at the equivalent time in non-stressed controls, they were 
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removed from their cages, anesthetized and the brain fixed by vascular perfusion, sectioned and 
processed to reveal Fos-like immunoreactivity. For each animal, the density of Fos-positive cells 
was sampled in 4 representative coronal sections through the PAG taken at antero-posterior levels 
-6.04, -7.04, -7.8 and -8.72 (Paxinos and Watson, 1986). For further details of the Method see 
Supplementary file. 
 
2.5 Data analysis 
The data was analysed using repeated measures two-way or one-way ANOVA, as appropriate 
with post hoc comparisons, or student’s t-test as appropriate. Full details of statistical methods are 
available in the Supplementary Methods file. 
 
3. Results 
3.1 Neurochemical studies  
3.1.1 Effect of fluoxetine on allopregnanolone concentration in late diestrus.  
Allopregnanolone was detected in the brain tissue of all animals. However, in the FLX-treated 
group (n=5) the concentration was more than double that measured in the saline-treated group 
(n=6) (*P<0.01, unpaired t-test, Fig. 1A). 
 
3.1.2. Effect of fluoxetine on extracellular brain 5-HT concentration in late diestrus. 
Microdialysis samples for 5-HT measurement were taken after the second dose of FLX, i.e. at the 
equivalent time to when other rats were used for the behavioral testing or the collection of brain 
samples for ALLO measurement. One group of rats used for microdialysis received the same low 
doses of FLX (2 x 1.75 mg kg-1) as animals used for the behavioral and neurochemical studies.  In 
these rats that received the lower dose of FLX (1.75 mg kg-1) the concentration of 5-HT taken in 
the period immediately prior to the second drug injection did not differ from the saline control 
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group (1.5 0.15 pg l-1 v. 2.40.42 pg l-1 respectively). However, in the group that received the 
higher doses of FLX (2 x 10 mg kg-1), the concentration of 5-HT prior to the second injection 
(3.81.07 pg l-1), was significantly higher than the saline-treated group (p<0.05, one-way 
ANOVA followed by Newman Keuls), presumably reflecting inhibition of serotonin re-uptake by 
this dose.  
After the second injection of FLX, post-hoc comparisons showed that the lower dose of FLX 
(1.75mg kg-1), i.e. the same dose as used in behavioral studies, still had no effect on the 
extracellular concentration of 5-HT in the dialysate compared to control group (p > 0.05) (Fig 1B). 
In contrast, the second higher dose of FLX (10mg kg-1) caused a significant decrease in the 
concentration of 5-HT in the dialysate compared to baseline samples of the same group (p < 0.05) 
(Fig 1B).  The minimum concentration of 5-HT (0.780.35 pg l-1) measured was above the lower 
limit of detection of our system (approximately 0.5 pg l-1).  Histological analysis revealed that all 
the dialysis probes were localized to the dorsal PAG (Fig. 1C). 
 
3.2. Behavioral testing 
3.2.1 Effect of fluoxetine on the development of stress-induced hyperalgesia during late 
diestrus 
Baseline tail flick latencies were similar at all stages of the estrous cycle and regardless of drug 
treatment status. In non-stressed controls and in saline-injected rats, tail flick latency did not 
change significantly over the course of the experiment (Fig 2). However, following exposure to 5 
min vibration stress, the vehicle-treated animals in late diestrus, but not at other cycle stages, 
displayed hyperalgesia, manifested as a significant decrease in tail flick latency (TFL), lasting 20 
min (Fig. 2).  Administration of FLX (2 x 1.75mg kg-1 i.p) to rats in the late diestrus phase had no 
effect on baseline TFLs but blocked completely the development of stress-induced hyperalgesia 
(Fig 2).  
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3.2.2. Estrous cycle-linked changes in PAG-evoked fearful behavior - effect of fluoxetine.  
In each rat the effect of electrical stimulation of the PAG was tested on 4 consecutive days i.e. at 
different stages of its estrous cycle.  There was a significant estrous cycle-linked effect on the 
stimulus intensity required to evoke different aspects of fear-like behavior, as documented below. 
Freezing and escape behaviors 
Two-way ANOVA with repeated measures considering estrous cycle stage and treatments as the 
factors applied for freezing behavior showed signicant differences between the stages of the 
estrous cycle but not between treatments. Also there was a significant interaction between the 
factors. Post-hoc comparisons indicated that the dPAG stimulation current intensity, which 
evoked freezing behavior, was significantly lower in late diestrus compared to other periods of the 
estrous cycle (n=7, p < 0.05) (Figs. 3A).  Post-hoc comparisons for escape behavior determined 
that it was evoked at lower currents in late diestrus compared to proestrus and early diestrus (Fig. 
3B). The analysis also clearly indicated that pre-treatment with FLX in late diestrus (n=10) 
prevented the estrous cycle-linked increase in sensitivity of the dPAG (Figs 3A and 3B).  In 
contrast to the saline-treated rats, the threshold current required for eliciting freezing and escape 
behaviors in late diestrus in fluoxetine-treated rats did not differ from thresholds at other stages of 
the cycle. 
 
Post-escape freezing
Two-way ANOVA with repeated measures applied on the duration of post-escape freezing 
behavior showed no difference between treatments or an interaction between treatments and stages 
(Fig. 3C). 
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Order of testing 
In both the saline and FLX-treated group of animals, there was no correlation between thresholds 
for evoking fear-like behaviors and the cycle stage at which the first test was carried out. In the 
saline-treated rats the lowest thresholds always occurred during the late diestrus phase regardless 
of whether the rat was being tested for the first time or had been tested previously when in another 
stage of the estrous cycle. Similarly, there was no evidence for the development of tolerance to 
repeated testing over the 4 days of the experiment, regardless of the stage at which the rat was first 
tested (p > 0.05 in all cases). In all groups, the electrode placements were localized to the dorsal 
half of the PAG (dPAG) (Fig. 4). 
 
3.3 Functional activation of neurons in the PAG.  
We investigated expression of the immediate early gene c-fos as an index of functional activation 
of the PAG circuitry. In the animals that had undergone behavioral testing for stress-induced 
hyperalgesia (see above), Fos-like immunoreactivity was present in nuclei throughout the PAG. 
For the control rats (no vibration stress) the density of labelled cells was similar at all cycle stages 
(Fig. 5). And in rats that were exposed to 5min of vibration stress, the number of labelled cells 
present in the PAG in proestrus, estrus and early diestrus was not significantly different from the 
non- stressed rats. However, in rats in late diestrus, fewer labelled cells were present in 
comparison to other stages of the cycle, an effect which was most pronounced in the lateral part of 
the rostral half of the PAG (Fig. 5).  This effect of vibration stress in LD was blocked completely 
by pre-treatment with FLX.  Indeed, after FLX in late diestrus the number of Fos-immunoreactive 
cells in the PAG following vibration stress was increased significantly compared to saline-treated 
rats (Fig. 5). The effect of FLX was most pronounced in the lateral column of the rostral half of 
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the PAG where there was a threefold increase in the number of labelled cells compared to saline-
treated controls (Fig. 5). 
 
4. Discussion 
In the present study, 5min exposure to anxiogenic vibration stress induced hyperalgesia during late 
diestrus but not at other stages of the cycle, as shown previously (Devall et al., 2009). 
Interestingly, during nociceptive flexor reflex threshold testing in women (arguably also a mildly 
stressful procedure) a mild hyperalgesia has been demonstrated during the luteal phase, similar to 
our finding in rats (Tassorelli et al., 2002). In addition, in the present study the thresholds for fear-
like freezing and escape behavior evoked in response to direct electrical stimulation in the dPAG 
were found to be lower in late diestrus compared to other cycle stages. Changes in motor control 
seem an unlikely explanation for this effect since freezing and escape are opposing locomotor 
responses, yet both were sensitive in the same way to estrous cycle stage, i.e. a lowered threshold 
for evoking the responses in late diestrus. It also seems unlikely that the effect of PAG stimulation 
in late diestrus was pain related since it was blocked by fluoxetine, which is not known to have 
analgesic properties. Fluoxetine also prevented the development of vibration stress-evoked 
hyperalgesia in late diestrus as well as the reduction in the expression of Fos-like 
immunoreactivity in the PAG in response to the vibration stress. 
The dose of fluoxetine chosen for this study (1.75mg Kg-1 i.p.) was at the lower end of the 
range reported to raise brain ALLO concentration in male rats (Uzunov et al., 1996), which was 
the only data available at the time our study began.  Similar findings were subsequently reported 
in male mice by Pinna et al. (2009) and Serra et al. (2001), who showed that fluoxetine could raise 
brain ALLO concentration at doses below the threshold for effects on 5-HT systems. Indeed, the 
EC50s for an influence of fluoxetine on ALLO were 10-50 times lower than the EC50 required to 
inhibit 5-HT reuptake. Based on these findings it is possible that an even lower dose of fluoxetine 
might have been effective in the present study. Nevertheless, at the present dosage of FLX used to 
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prevent the stress-induced hyperalgesia of female rats in late diestrus, brain ALLO concentration 
was raised yet there was no change in the extracellular concentration of 5-HT in the dPAG. We 
cannot rule out an action of fluoxetine on 5-HT systems in other brain regions. However, the 
published data in males suggests that the dose we used would at best produce only small, transient 
effects (see Fig 1 of Rutter and Auerback, 1993).  Moreover, fluoxetine has been shown to be less 
effective in raising extracellular 5-HT concentration in females compared to males after acute 
administration (Masswood et al, 1999). Thus it is most likely that the effects of fluoxetine in the 
present study were due its effects on neurosteroid synthesis rather than 5-HT systems. 
In female rats, ALLO in the brain appears to arise predominantly from local metabolism of 
ovarian progesterone, with a significant correlation between brain ALLO and plasma progesterone 
across the estrous cycle (Corpechot et al., 1993). At late diestrus there is a sharp fall in plasma 
progesterone (Butcher et al., 1974) and the ovarian secretions of both this steroid and ALLO fall 
to the lowest values across the cycle (Ichikawa et al., 1974; Holzbauer, 1975). In male rats and in 
mice, a single dose (18 mg kg-1) of fluoxetine produces a rapid onset (<15 min) increase in the 
brain concentration of ALLO, followed by a more gradual fall (> 2 h; Uzunov et al., 1996; Pinna 
and Rasmusson 2012). The elevation of brain ALLO by fluoxetine was thought to be due to an 
activation of the aldo-keto reductase enzyme, which produces this steroid from 5-
dihydroprogesterone (Griffin and Mellon 1999). Such a mechanism has been questioned however 
(Trauger et al., 2002) and we have shown recently that FLX raises ALLO concentration in female 
rat brain by inhibiting the microsomal dehydrogenase oxidising ALLO to 5-DHPROG (Fry et al., 
2014 in press). Acute treatment with FLX has been shown to inhibit the cytochrome CYP2C11 
enzyme in liver (Wójcikowski et al., 2013) but this would not be expected to influence the 
synthesis of ALLO.  
In our spontaneously cycling female rats, the short term dosage beginning late in the 
afternoon of early diestrus with a second dose on the morning of late diestrus, likely offset the 
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sharp decline in plasma and brain ALLO that normally occurs in late diestrus. However, 
administration of FLX did not simply shift the withdrawal effect on by a day since thresholds for 
evoking fear-related behaviors by electrical stimulation of the PAG a day later in proestrus were 
no different from saline-treated animals. The major metabolite of FLX is norfluoxetine, which 
Pinna et al. (2009) have shown to be more potent than FLX itself at elevating mouse brain ALLO 
and which in rat brain has a half-life of around 8h following a single dose (Qu et al., 2009).  Thus 
it is likely that after administration of FLX in the current study, the brain concentration of ALLO 
was elevated throughout late diestrus. 
 Behavioral evidence for the estrous cycle-linked change in excitability of the PAG was 
accompanied by evidence of changes in the functional activation of neurons induced by exposure 
to mild anxiogenic vibration stress. Thus, in the early stages of the cycle (i.e. proestrus, estrus and 
early diestrus), exposure to the stressor failed to evoke a significant change in Fos expression in 
the PAG. This contrasted with late diestrus, when the vibration stress significantly lowered the 
number of Fos-positive neurons, particularly in the rostral half of the nucleus in the dorsal, 
dorsolateral and lateral columns.  These results imply deactivation of a tonically active cell 
population in response to the acute stress applied during late diestrus.  Reduced activation within 
GABAergic populations induced by stress is not unprecedented.  In male rats, reduced activation 
of GABAergic neurons in the prefrontal cortex (i.e. fewer Fos-positive cells present) was reported 
following exposure to a novel anxiogenic stress (Weinberg et al., 2010) whilst a decrease in 
extracellular concentration of GABA has been observed in the PAG during contextual fear (Rea et 
al., 2009). Two recent studies in women also showed acute stress-evoked deactivation in the 
BOLD fMRI signal in both the PAG and the medial prefrontal cortex during the late 
follicular/mid-cycle (Goldstein et al., 2010) and the late luteal (Ossewaarde et al., 2010) phase of 
the menstrual cycle, the latter coinciding with increased sensitivity to acute emotional stress 
(Goldstein et al., 2010; Ossewaarde et al., 2010), as seen during the analogous ovarian cycle stage 
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in rats (see Introduction).  
Although the phenotype/s of the Fos-labelled cells in the PAG in the present study was not 
identified, a stress-induced deactivation of the intrinsic GABAergic interneurone population 
during late diestrus would be consistent with the above findings in women. Afferent input from 
nociceptors is modulated at the spinal level by tonic activity in descending facilitatory and 
inhibitory systems that originate in the PAG (Gebhart, 2004). Under normal circumstances, the 
balance between the activity in these systems has been suggested to be biased towards facilitation, 
at least in males (Bee and Dickenson, 2008). Stress-induced inhibition of GABA tone on these 
control systems during late diestrus in females, might tip the balance further in favor of 
facilitation, thereby lowering the threshold for evoking nociceptive reflexes such as the tail flick. 
GABAergic neurones are present throughout the PAG of the rat and are especially populous in the 
dorsolateral sector (Griffiths et al., 2005a; Griffiths et al., 2005b; Lovick and Paul, 1999).  In the 
cat they constitute some 36% of the total population in this sector (Barbaresi, 2005). In late 
diestrus or after withdrawal from dosing with exogenous progesterone, expression of 4, 1 and  
GABAA receptor subunits on the GABAergic interneuron population in the PAG is upregulated, 
triggered by the declining brain concentration of progesterone (and hence ALLO) (Griffiths and 
Lovick, 2005a; 2005b). Since 4, 1 and  subunits can co-assemble to form functional receptors 
(Lovick et al., 2005) and the presence of  subunits indicates an extrasynaptic location (Farrant 
and Nusser, 2005), the tonic current carried by the interneurone population of the PAG would 
increase. Indeed, we have shown in vivo, that the level of GABAergic tone, which regulates the 
excitability of the output neurons in the PAG, is reduced during late diestrus (Brack and Lovick, 
2007).  As a consequence, the circuitry becomes intrinsically more excitable, as reflected in the 
present study by the decrease at late diestrus in the threshold current required to evoke fear-like 
behaviors in response to electrical stimulation of the dPAG.  
The above changes in behavior of the rats were associated with changes within the PAG at 
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the cellular level. Rather than simply normalizing Fos expression in late diestrus to the level seen 
in earlier stages of the cycle, FLX treatment transformed the stress-induced decrease in the 
number of fos-positive neurons in the PAG in late diestrus into a large increase in labelled cells, 
most prominently in the lateral column at mid-PAG level. Thus in the presence of FLX, the 
circuitry appeared to process the stress-inducing stimulus in a quite different way. This may reflect 
functional changes within the PAG circuitry itself and/or changes in afferent input from other 
structures involved in the processing of stress-inducing stimuli.   
Fluoxetine was developed originally as a selective serotonin reuptake inhibitor and is one of 
the most widely used antidepressant drugs worldwide. Its clinical effectiveness as an 
antidepressant typically requires a long lead in period and exacerbation of adverse symptoms is 
not uncommon in the short term. In male rats, acute administration of FLX at doses that show 
anxiolytic or anti-aversive effects after long-term treatment is actually anxiogenic (Silva and 
Brandao, 2000). Yet in the present study of females in late diestrus, FLX appeared anxiolytic at 
the low dose (2 x 1.75mg kg-1) used. Moreover, this low dose of FLX failed to produce a 
significant change in extracellular 5-HT concentration in the dPAG, suggesting that its effects on 
behavior were not due to an action on 5-HT systems.  
The lack of effect of the lower dose of FLX (2 x 1.75mg kg-1) used in the present study on 
extracellular 5-HT concentration in the PAG was not due to insufficient sensitivity of our system, 
because the basal concentration of 5-HT was above the threshold for detection. Moreover, a 
change in 5-HT concentration was observed in response to a higher dose of FLX (2 x 10mg kg-1).  
Indeed the second higher dose of FLX, which we had used only to check the responsiveness of our 
microdialysis system, produced a significant decrease in the extracellular concentration of 5-HT in 
the dPAG.  At first sight this finding appeared at odds with the reported rise in extracellular 5-HT 
in the PAG after acute administration of FLX in males (Zanoveli et al., 2010). However, in the 
dosing protocol used for our study in females the rats received FLX on two occasions: once on the 
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evening of early diestrus and again on the morning of late diestrus immediately before the 
microdialysis samples were taken.  In the female rats that received the higher dose of FLX (10 mg 
kg-1) the basal concentration of 5-HT before the second injection was given was significantly 
higher than in the control group. This suggests that the higher dose of FLX had blocked serotonin 
re-uptake in the PAG, as it does in males (Zanoveli et al., 2010).  Against the raised basal level, a 
second injection of FLX might be expected to raise extracellular 5-HT further. However, a further 
rise in 5-HT in the dorsal raphe nucleus (DRN), the major source of serotonergic input to the 
PAG, may have lead to activation of 5-HT1A somatodendritic autoreceptors, which would depress 
the activity of the DRN population (Rutter and Auerbach, 1993; Hajos et al., 2001) and reduce 5-
HT output in the PAG, as seen in the present experiments.  Whilst these possibilities are 
intriguing, further investigation was outside the scope of the present study.  
ALLO has been shown to produce a modest increase the firing of 5HT neurons in the DRN 
after acute intracerebroventricular administration to anaesthetised rats (Robichaud and Debonnel, 
2006). However, in that study the dose given of 1μg kg-1 icv would be expected, assuming an even 
distribution within the brain and without loss to the periphery, to give an ALLO concentration of 
about 0.15g g-1 of brain for a 250-325g rat (Bailey et al., 2004). This is some 50 times higher 
than the ALLO concentration of 3ng g-1 brain measured after FLX treatment in the present study 
in females. Moreover, there was no change in the extracellular concentration of 5-HT in the PAG, 
which might have been expected if the FLX-induced rise in ALLO concentration had been 
sufficient to stimulate the 5-HT neurons in the DRN. Another possibility is that FLX could have 
influenced GABA release in the PAG or elsewhere via activation of the 5-HT2A receptors that are 
present on GABAergic neurones in the PAG (Griffiths and Lovick, 2002). However, since our 
dose of FLX did not influence extracellular 5-HT concentration in the PAG, it is unlikely that 
these cells would have been influenced. 
Our current findings in a rat model indicate that the increased responsiveness to acute 
 19
anxiogenic stress seen at late diestrus can be prevented by administration of FLX, which induces 
an increase in brain ALLO timed to offset the physiological decrease in the steroid expected at this 
stage of the ovarian cycle. The timing of FLX treatment appears to be critical, since dosing at 
other cycle stages had no effect on behavior. Moreover in a recent study using an exogenous 
progesterone withdrawal regimen, long-term treatment with FLX, albeit at a higher dose than that 
used in the present study, had no effect on the withdrawal response (Li et al., 2012). The 
pharmacological action of FLX might therefore be related to its ability to alter the rate of change 
of brain ALLO across the cycle rather than simply producing an increase in basal concentration. 
This would be consistent with our recent discovery that fluoxetine inhibits the oxidative 
inactivation of ALLO (Fry et al., 2014, in press).  
In women, short term administration of FLX during the late luteal phase or after a single 
dose of a delayed release formulation, starting a few days before adverse premenstrual symptoms 
arise, could similarly produce a gradual tapering in brain concentration of this steroid over several 
days and thereby offset the precipitous fall in ALLO that occurs naturally. Fluoxetine is 
particularly suited to produce such an effect, with a long plasma half-life, which is seen also for its 
active metabolite norfluoxetine: 1- 4 and 7-15 days respectively after a single dose (Hiemke and 
Härtter, 2000). Moreover, if women at the late luteal phase are comparable to the late diestrus rats 
of the present study in requiring only a low dose of FLX to elevate brain ALLO concentration, 
then adverse side effects should be absent or minimal.  
To conclude, short-term administration of a low dose of fluoxetine during late diestrus in the 
rat raises brain ALLO concentration and blunts the abrupt fall in this progesterone metabolite, 
which normally occurs at this stage of the ovarian cycle, due to the sudden decline in ovarian 
progesterone secretion. The trigger for the neuronal withdrawal response, which precipitates the 
development of anxiety-like behavior under stressful circumstances, is therefore absent. We 
suggest these observations in the rat provide an explanation for the efficacy of fluoxetine in the 
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treatment of PMS (see Majoribanks et al., 2013). If we are correct, then short term treatment with 
fluoxetine given at doses below the antidepressant threshold but tailored to elevate brain 
allopregnanolone during the premenstrual period, could explain both the rapid response of PMDD 
patients to fluoxetine (Steinberg et al., 2012) and the effectiveness of intermittent dosing with this 
drug in the treatment of the disorder (Steiner et al., 1997).  Moreover, by determining the 
magnitude and rate of the decline in progesterone for each individual, it should be possible to 
personalise the treatment to select the minimum effective dose of fluoxetine for the patient.  
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Figures captions 
Fig. 1. A. Increase in brain concentration of ALLO (mean S.E.M.) in rats in late diestrus treated 
with fluoxetine (FLX, 1.75mg kg-1 i.p., n=5) or saline vehicle (VEH, n=6) on the afternoon of 
early diestrus and again on the morning of late diestrus, (LD) 60 min before sacrifice. *P<0.01, 
unpaired t-test.
B. Extracellular concentration of 5-HT in the PAG of rats in late diestrus treated with fluoxetine (2  
x 1.75 mg kg-1, n=6 or 2 x 10 mg kg-1, n=4  or saline, n=4 using the i.p. dosing regimen as above). 
Arrow indicates time of injection on morning of late diestrus. All values means  S.E.M.  *P<0.05 
with respect to mean baseline, repeated measures two-way ANOVA with Tukey’s test. 
C. Location of dialysis probes (solid bars) plotted onto outlines of coronal sections through the 
PAG taken from the atlas of Paxinos and Watson (2007). Numbers below drawings indicate mm 
caudal to bregma. 
Fig. 2. Effect of 5 min of vibration stress (gray bar) on tail flick latency (TFL) in female rats at 
different stages of the estrous cycle and following fluoxetine treatment. Administration of 
fluoxetine (FLX 1.75 mg kg-1 i.p.) or vehicle (saline, i.p.) was carried out on the evening of early 
diestrus and again 1 h before behavioral testing commenced in late diestrus the next morning. All 
values (mean ± SEM) are expressed as a percentage of mean pre-stress baseline values. 
Abbreviations: P: proestrus; E: estrus; ED: early diestrus; LD: late diestrus. * P<0.05, ** P<0.01, 
two-way ANOVA compared to baseline. § P<0.05, §§§ P<0.001, two-way ANOVA compared to 
vehicle (n=8 to10 per group). 
Figure 3. Estrous cycle-linked effects on responses to electrical stimulation of the dPAG. 
Threshold currents to evoke freezing (A) and escape behavior (B). The duration of post-escape 
freezing is shown at C. For each rat thresholds were measured on the 4 days of its cycle.  Saline 
(vehicle control, n=7) or fluoxetine (1.75mg Kg-1 i.p, n=10) was administered on the afternoon of 
early diestrus and again 1h prior to beginning testing on the morning of late diestrus. 
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Abbreviations P: proestrus; E: estrus; ED: early diestrus; LD: late diestrus; SAL: saline; FLX: 
fluoxetine. Data expressed as means ± S.E.M. * p < 0.05 compared to the other periods of the 
estrous cycle for freezing and to P and ED for escape and post-stimulation freezing behavior 
(Fischer´s LSD post-hoc test after significant repeated measures one-way ANOVA); # p < 0.05 
significant interaction between treatments and stage of estrous cycle. 
Fig 4. Left: Photomicrograph showing location of electrode track in the dorsal PAG in a 
representative animal. Right: Stimulation sites in the dorsal PAG plotted onto representative 
outline sections of the PAG taken from the atlas of Paxinos and Watson (2007). o: no drug 
(n=12); *: saline-treated rats (n = 7); : fluoxetine-treated rats (n = 10). Numbers below sections 
indicate distance from bregma.  
 
Fig. 5. A. The density of Fos-positive nuclei in 5 longitudinal columns in the rostral (levels I & II) 
and caudal (levels III & IV) halves of the PAG. Panel B shows the effect of vibration stress and 
fluoxetine (1.75 mg kg-1 i.p.) treatment in late diestrus on the density of Fos-positive nuclei in 
whole extent of the PAG observed at each stage of the estrous cycle.  Panel C shows detailed 
effect of FLX in different columns of the rostral (levels I and II) and caudal (levels III and IV) 
PAG in late diestrus. All values mean ± SEM, n=5-6 per group. Abbreviations: P: proestrus; E: 
estrus; ED: early diestrus; LD: late diestrus. *** P<0.001, ** P<0.01, * P<0.05, § significantly 
different from stressed animals in proestrus, estrus and early diestrus (P<0.05), two-way ANOVA 
with Bonferroni’s test. 
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